ConductScience.org, home

Paper38366267

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.

Ivy D and 8 others. Eur J Pediatr, 2024. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study. Papers, record 38366267. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38366267

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
PubMed
Journal
Eur J Pediatr
PubMed
Year
2024
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Multicenter Study
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.79, provisional
iCite
Revised in PubMed
2024-05-16
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ivy DDunbar
2Beghetti MMaurice
3Juaneda-Simian EErnesto
4Ravindranath RRamiya
5Lukas MAMary Annhttps://orcid.org/0000-0003-0791-5580
6Machlitt-Northen SSandra
7Scott NNicola
8Narita JJun
9Berger RMFRolf M F

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PyridazinesMajor topic
PhenylpropionatesMajor topic
Pulmonary Arterial HypertensionMajor topic
Humans
Male
Child
Female
Adolescent
Treatment Outcome
Antihypertensive Agents
Dose-Response Relationship, Drug
Walk Test
Hypertension, Pulmonary

Source PubMed

Download CSV of topics

References10

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133765691Endothelin receptor antagonists for pulmonary arterial hypertension.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/33765691PubMed
2360175482022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur Heart J2022https://conductscience.org/library/papers/36017548PubMed
321947294Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.Circulation2011https://conductscience.org/library/papers/21947294PubMed
48497283Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.N Engl J Med1993https://conductscience.org/library/papers/8497283PubMed
521419223The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension.Pharmacol Res2011https://conductscience.org/library/papers/21419223PubMed
637332660A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years.J Pediatr X2020https://conductscience.org/library/papers/37332660PubMed
718506008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Circulation2008https://conductscience.org/library/papers/18506008PubMed
822511577Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.Pediatr Pulmonol2013https://conductscience.org/library/papers/22511577PubMed
936579617Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data.J Clin Pharmacol2023https://conductscience.org/library/papers/36579617PubMed
1026386921FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.Int J Cardiol2016https://conductscience.org/library/papers/26386921PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42390808SGLT2i, anti-endothelin A and double endothelin and angiotensin inhibitors: a new future for chronic kidney disease in children.Pediatr Nephrol2026https://conductscience.org/library/papers/42390808PubMed
41923739Synergistic Cardiopulmonary Protection of Endothelin Receptor Antagonists Combined With Soluble Guanylate Cyclase Agonists in High-Risk Coronary Syndrome With Pulmonary Hypertension.Rev Cardiovasc Med2026https://conductscience.org/library/papers/41923739PubMed
39734932Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension.Pulm Circ2024https://conductscience.org/library/papers/39734932PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38366267

GET https://conductscience.org/api/papers/v1/38366267/authors